domingo, 22 de abril de 2018

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

Main|Search|PHGKB

Pharmacogenomics




Last Posted: Apr 20, 2018


No hay comentarios:

Publicar un comentario